Recent Finacing
Recent Raise
Soteria Biotherapeutics develops small molecule–activated, switchable bispecific T-cell engagers via its T-LITE platform to enable pulsatile activity, reduced side effects and higher dosing for solid tumors.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Soteria Biotherapeutics.
